Profile of:
Giuseppe Lopalco
WORK EXPERIENCE: MD Resident in Rheumatology, University of Bari “Aldo Moro”, School of Medicine, School of Rheumatology from June 2009 to 17th June 2014 Assistant Research Fellow at Rheumatology Unit, University of Siena from September 2013 to December 2013 Rheumatology Consultant at Rheumatology Unit of University of Bari “Aldo Moro”, Bari (IT) from Dicember 2014 to June 2021 Associate Professor of Rheumatology at Rheumatology Unit of University of Bari “Aldo Moro”, Bari (IT) since 3rd June 2021 AREAS OF RESEARCH/INTEREST: Spondylarthritis, Behçet’s disease, Autoinflammatory diseases, Systemic Vasculitis, Rheumatoid Arthritis, Rare Rheumatic diseases, Ocular inflammatory diseases, Idiopathic pericarditis OTHER MEMBERSHIPS: Italian Society of Rheumatology (SIR) - Autoinflammatory Diseases Working Group of the Italian Society of Rheumatology - AIDA Network Academy
Full name: Giuseppe Lopalco
Current country: Italy
Membership level: Full
Type of membership: Member
Number of publications: 16
Uncovering the Underworld of Axial Spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37047435/
Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet’s Syndrome and Psoriatic Arthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/37240162/
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) (2023)
https://pubmed.ncbi.nlm.nih.gov/37324154/
Beyond the horizon: Innovations and future directions in axial-spondyloarthritis (2023)
https://pubmed.ncbi.nlm.nih.gov/38125058/
Immunogenicity of BNT162b2 mRNA SARS-CoV-2 vaccine in patients with psoriatic arthritis on TNF inhibitors (2022)
https://pubmed.ncbi.nlm.nih.gov/34987092/
A Machine Learning Approach to Predict Remission in Patients With Psoriatic Arthritis on Treatment With Secukinumab (2022)
https://pubmed.ncbi.nlm.nih.gov/35833126/
Anti-SARS-CoV-2 antibody decay after vaccination and immunogenicity of the booster dose of the BNT162b2 mRNA vaccine in patients with psoriatic arthritis on TNF inhibitors (2022)
https://pubmed.ncbi.nlm.nih.gov/36441661/
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA (2021)
https://pubmed.ncbi.nlm.nih.gov/32755721/
High disease relapse after bDMARD spacing in psoriatic arthritis compared to rheumatoid arthritis and axial spondyloarthritis patients: real-life data from BIOPURE registry (2021)
https://pubmed.ncbi.nlm.nih.gov/33864158/
Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/31652315/
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis (2020)
https://pubmed.ncbi.nlm.nih.gov/32317863/
Serum sCD40L levels are increased in patients with psoriatic arthritis and are associated with clinical response to apremilast (2020)
https://pubmed.ncbi.nlm.nih.gov/32383167/
Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. (2019)
https://pubmed.ncbi.nlm.nih.gov/31025925/
Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings (2018)
https://pubmed.ncbi.nlm.nih.gov/30079593/
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. (2018)
https://pubmed.ncbi.nlm.nih.gov/30109794/
Long-term safety of anti-TNF agents on the liver of patients with spondyloarthritis and potential occult hepatitis B viral infection: an observational multicentre study (2017)
https://pubmed.ncbi.nlm.nih.gov/27974094/
